BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 24161422)

  • 1. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
    Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
    Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
    Wan J; Liu K; Li K; Li G; Zhang Z
    Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Chemotherapy Regimens on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Rectal Cancer Patients Receiving Intensity Modulated Radiation Therapy With Concurrent Chemotherapy From a Prospective Phase III Clinical Trial.
    Cheng Y; Ma Y; Zheng J; Deng H; Wang X; Li Y; Pang X; Chen H; He F; Wang L; Wang J; Wan X
    Front Oncol; 2019; 9():244. PubMed ID: 31024846
    [No Abstract]   [Full Text] [Related]  

  • 7. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
    Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Med Oncol; 2016 Dec; 33(12):137. PubMed ID: 27815805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.
    Cheng JC; Bazan JG; Wu JK; Koong AC; Chang DT
    Pract Radiat Oncol; 2014; 4(3):198-206. PubMed ID: 24766688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
    Newman NB; Sidhu MK; Baby R; Moss RA; Nissenblatt MJ; Chen T; Lu SE; Jabbour SK
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1052-60. PubMed ID: 27026312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
    Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
    Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
    Rose B; Mitra D; Hong TS; Jee KW; Niemierko A; Drapek LN; Blaszkowsky LS; Allen JN; Murphy JE; Clark JW; Ryan DP; Wo JY
    Pract Radiat Oncol; 2017; 7(5):e291-e297. PubMed ID: 28462895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
    Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
    Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
    Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
    Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
    Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
    Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.